UBS Group
PPH icon

UBS Group’s VanEck Pharmaceutical ETF PPH Stock Holding History

UBS Group’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,300
Closed -$2.42M – 10902
2026
Q1 		$2.42M Buy
+23,300
New +$2.48M ﹤0.01% 4798

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group's PPH Position: Q2 2026 in Review

UBS Group increased its VanEck Pharmaceutical ETF (PPH) stake by 842% in Q2 2026, buying an estimated $47.9M and bringing the position to 517,756 shares worth $56.6M. The position accounts for 0.01% of the portfolio, ranked #1621.

UBS Group first reported a position in PPH in Q4 2014 and has held it in 47 quarters since. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

  • UBS Group held 517,756 shares of VanEck Pharmaceutical ETF worth $56.6M as of Q2 2026.
  • UBS Group bought 462,792 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $47.9M.
  • VanEck Pharmaceutical ETF made up 0.01% of UBS Group's portfolio in Q2 2026, its #1621 holding.
  • UBS Group first reported a position in VanEck Pharmaceutical ETF in Q4 2014 and has held it in 47 quarters since.
  • 148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.